Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Market Cap	1.11B +140.7%
Revenue (ttm)	35.81M +24.1%
Net Income	-224.02M
EPS	-0.97
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,980
Average Volume	9,425
Open	482.10
Previous Close	482.10
Day's Range	473.60 - 485.00
52-Week Range	136.90 - 666.00
Beta	1.75
RSI	39.60
Earnings Date	Mar 13, 2026

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 77
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: LCTX

Financial Performance

In 2024, Lineage Cell Therapeutics's revenue was $9.50 million, an increase of 6.19% compared to the previous year's $8.95 million. Losses were -$18.61 million, -13.39% less than in 2023.

Financial numbers in USD